HCW Biologics Inc. Common Stock (HCWB) is a publicly traded Healthcare sector company. As of May 21, 2026, HCWB trades at $2.14 with a market cap of $9.02M and a P/E ratio of -0.38. HCWB moved +133.49% today. Year to date, HCWB is +118.92%; over the trailing twelve months it is -73.53%. Its 52-week range spans $0.25 to $100.80. Analyst consensus is buy with an average price target of $2.00. Rallies surfaces HCWB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
HCW Biologics EPS Beats, $6.54M Revenue on Licensing Fuel 122% Surge: HCW Biologics reported Q1 2026 EPS of $0.37 versus a $0.44 loss estimate and revenue of $6.54 million, up from $5.06 million year-over-year. Revenue growth was driven by a licensing agreement with Beijing Trimmune that delivered $3.5 million in cash and $3.5 million in equity, though the company faces a 0.09 current ratio and going concern doubts.
| Metric | Value |
|---|---|
| Price | $2.14 |
| Market Cap | $9.02M |
| P/E Ratio | -0.38 |
| EPS | $-7.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $100.80 |
| 52-Week Low | $0.25 |
| Volume | 1.67M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.55M |
| Net Income | $-2.29M |
| Gross Margin | 99.89% |
1 analysts cover HCWB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.00.